On March 27, 2026, OnKure Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel precision medicines, announced that it has entered into a securities purchase agreement for a private placement with certain institutional and accredited healthcare investors, raising gross proceeds of approximately $150 million. Wilson Sonsini Goodrich & Rosati advised OnKure on the transaction.

The Wilson Sonsini team that advised OnKure on the transaction includes Jennifer Knapp, Phil McGill, Austin Day, Jacob Morales, and Angelica Lee.

For more information, please see OnKure’s news release.